Holen Sie sich die Stockscreener-App
39.02
1.86%
-0.73
Handel nachbörslich:
39.06
0.04
+0.10%
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Healthcare Technology Stocks Q3 Teardown: Hims & Hers Health (NYSE:HIMS) Vs The Rest - The Globe and Mail
Options Corner: Hims & Hers Health's Downturn Presents A Compelling Opportunity For Quants - Benzinga
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care - Yahoo Finance
How Trump’s GLP-1 move may affect telehealth companies’ fortunes - Modern Healthcare News
Is Hims & Hers Health Worth a Look After 23.9% Pullback in 2025? - Yahoo Finance
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade) (NYSE:HIMS) - Seeking Alpha
Why Hims & Hers Health (HIMS) Is Down 7.6% After Narrowing 2025 Revenue Guidance and Q3 Results - Yahoo Finance
Hims & Hers: The Profitability Squeeze Amidst Rapid Expansion - AD HOC NEWS
Hims & Hers Health’s Q3 Earnings Call: Our Top 5 Analyst Questions - The Globe and Mail
Hims & Hers Health Soars on Strong Growth and Strategic Shifts - NAI500
Hers Health Inc. stock continue upward trendJuly 2025 Institutional & Weekly Top Performers Watchlists - newser.com
Hims & Hers Revenue Continues to Surge. Is It Time to Buy the Stock? - Yahoo Finance
Hims & Hers Stock: Navigating Regulatory Headwinds and Leadership Shifts - AD HOC NEWS
Hims & Hers Health Stock (HIMS) Opinions on Q3 Earnings and Expansion Plans - Quiver Quantitative
Hims & Hers Health Inc. Class A (HIMS) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care - Yahoo Finance
Why Analysts Say the Hims & Hers Health Story Is Shifting With New Opportunities and Risks - Yahoo Finance
How Novo Nordisk Gave Up Its Weight-Loss Gains - Bloomberg.com
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now? - Yahoo Finance
Hims & Hers Shares Tumble as Profit Miss Overshadows Revenue Growth - AD HOC NEWS
Can Hims & Hers Keep Its GLP-1 Edge After Trump Forces Lilly And Novo To Slash Prices? Wall Street Isn’t Convinced - Stocktwits
JPMorgan Chase & Co. Expands Holdings in Hims & Hers Health Inc. - GuruFocus
GLP-1 price cuts limit Hims advantage, says Needham - TipRanks
Sell Recommendation for Hims & Hers Health Amid Competitive Pricing Pressures and Projected Decline - TipRanks
TrumpRx GLP-1 pricing ‘less bad than feared’ for Hims & Hers, says Citi - TipRanks
Understanding Momentum Shifts in (HIMS) - news.stocktradersdaily.com
Hims & Hers Health (HIMS) Looks to Turn GLP-1 Hype Into Health Empire - MSN
Eli Lilly, Novo Nordisk Or A Dark Horse: Which Obesity-Drug Stock Are Retail Traders Most Bullish On Over Next 5 Years? - Stocktwits
1 Growth Stock to Stash and 2 We Ignore - The Globe and Mail
Hims & Hers Health Q3 2025 Earnings: Revenue Jumps 49%News and Statistics - IndexBox
Why Are Hims & Hers Health (HIMS) Shares Soaring Today - TradingView
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract - Yahoo Finance
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results - sharewise.com
Analysts Issue Forecasts for HIMS Q3 Earnings - MarketBeat
Hims & Hers: GLP-1 Partnership Could Unlock Value (NYSE:HIMS) - Seeking Alpha
Mission Wealth Management LP Acquires Shares of 10,300 Hims & Hers Health, Inc. $HIMS - MarketBeat
Teacher Retirement System of Texas Purchases 6,925 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Arkadios Wealth Advisors Acquires New Shares in Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers Health, Inc. (NYSE:HIMS) Q3 2025 Earnings Call Transcript - Insider Monkey
Hims & Hers Health (HIMS) Margin Compression Challenges Bullish Narratives Despite Sustained Profit Growth - Yahoo Finance
Promising Healthcare Stocks To Watch NowNovember 2nd - MarketBeat
Potential Wegovy Partnership Could Transform Hims & Hers Growth Trajectory - AD HOC NEWS
Hims & Hers Health, Inc. Reports Strong Growth and Strategic Optimism - TipRanks
White House nears deal to lower prices for weight loss drugs Wegovy and Zepbound - AOL.com
Hims & Hers gains as analysts welcome talks with Novo for Wegovy sales - MSN
Best Healthcare Stocks To Follow TodayNovember 4th - MarketBeat
Novo Nordisk’s Wegovy could soon have a new sales outlet in the U.S. - MSN
OMCL vs. HIMS: Which Stock Is the Better Value Option? - sharewise.com
HIMS Q3 Deep Dive: Personalized Offerings and Strategic Expansion Shape Telehealth Growth - The Globe and Mail
Hims & Hers Eyes Major Weight-Loss Breakthrough With Potential Novo Nordisk Wegovy Deal - Yahoo Finance
Hims shares rise on talks to offer Novo’s new obesity pill - The Detroit News
Deutsche Bank Adjusts Hims & Hers Health Price Target to $42 From $48, Maintains Hold Rating - MarketScreener
Hims & Hers rises after Q3 revenue beat - TradingView
BTIG Research Reiterates Buy Rating for Hims & Hers Health (NYSE:HIMS) - MarketBeat
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 - MarketBeat
Earnings live: Palantir stock rises modestly on strong results, Hims & Hers stock surges - Yahoo Finance
Hims and Hers tops revenue estimates as telehealth provider attracts more users - MSN
Hims Shares Rise on Talks to Offer Novo’s New Obesity Pill - Yahoo Finance
Biggest stock movers Tuesday: PLTR, SRPT, and more - MSN
Hims & Hers Plunges After Novo Split, Eyes Global Push - Value The Markets
Hims & Hers Stock (HIMS) Soars on Potential Deal to Offer Novo Nordisk’s Wegovy - TipRanks
Hims & Hers projects over $6.5B revenue by 2030 as global expansion and diagnostics strategy accelerates - MSN
Decoding Hims & Hers Health Inc (HIMS): A Strategic SWOT Insight - GuruFocus
Hims & Hers Health Inc (HIMS) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Hims & Hers Health Reports Strong Q3 2025 Growth - TipRanks
3.57%
0.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):